All In Biotech

Drug Trial Radar · NCT04700124

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 808 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

808

Actual

Start

Apr 21, 2021

Primary completion

Oct 27, 2025

Study completion May 18, 2028

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Seagen Inc.; Astellas Pharma Inc
First posted
Jan 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \[gemcitabine plus cisplatin\] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).

Conditions

  • Bladder Cancer

Interventions

  • PembrolizumabBiological

    200 mg of Pembrolizumab IV infusion, on Day 1 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 Q3W for 13 cycles in postoperative phase (up to approximately 9 months). The total duration of treatment is up to approximately 1 year.

  • Enfortumab vedotin (EV)Biological

    1.25 mg/kg of EV IV infusion, on Day 1 and Day 8 Q3W for 4 cycles (each cycle length = 21 days) in preoperative phase (up to approximately 3 months) and on Day 1 and Day 8 Q3W for 5 cycles (each cycle length = 21 days) in postoperative phase (up to approximately 4 months). The total duration of treatment is up to approximately 7 months.

  • RC + PLNDProcedure

    Curative intent RC + PLND surgery will be administered to all participants randomized to Arm A and B after completion of preoperative systemic treatment (RC + PLND to be done approximately at 15 weeks from randomization).

  • GemcitabineDrug

    1000 mg/m\^2 of Gemcitabine IV infusion, Day 1 and Day 8 Q3W for 4 cycles in preoperative phase (up to approximately 3 months)

  • CisplatinDrug

    70 mg/m\^2 of Cisplatin IV infusion, Day 1, Q3W for 4 cycles in preoperative phase (up to approximately 3 months)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free Survival (EFS)Time frame: Up to ~68 months

Locations

188 sites in 29 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix ( Site 0043)

    Phoenix, Arizona

  • St Joseph Heritage Healthcare-Oncology ( Site 0035)

    Fullerton, California

  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0005)

    Los Angeles, California

  • University of California San Francisco ( Site 0010)

    San Francisco, California

  • Stanford University ( Site 0023)

    Stanford, California

  • University of Colorado, Anschutz Cancer Pavilion ( Site 0009)

    Aurora, Colorado

  • UF Health ( Site 0031)

    Gainesville, Florida

  • Indiana University Melvin and Bren Simon Cancer Center ( Site 0050)

    Indianapolis, Indiana

  • University of Iowa Hospital and Clinics ( Site 0029)

    Iowa City, Iowa

  • University of Louisville, James Graham Brown Cancer Center ( Site 0022)

    Louisville, Kentucky

  • Icahn School of Medicine at Mount Sinai ( Site 0011)

    New York, New York

  • White Plains Hospital ( Site 0039)

    White Plains, New York

  • Duke University Medical Center ( Site 0017)

    Durham, North Carolina

  • Wake Forest Baptist Health ( Site 0014)

    Winston-Salem, North Carolina

  • Oregon Health and Science University ( Site 0028)

    Portland, Oregon

  • MidLantic Urology ( Site 0002)

    Bala-Cynwyd, Pennsylvania

  • Saint Francis Cancer Center ( Site 0008)

    Greenville, South Carolina

  • The University of Tennessee Medical Center ( Site 0034)

    Knoxville, Tennessee

  • UT Southwestern Medical Center ( Site 0003)

    Dallas, Texas

  • Houston Methodist Urology Associates ( Site 0033)

    Houston, Texas

  • Urology of San Antonio ( Site 0020)

    San Antonio, Texas

  • University of Wisconsin Hospital and Clinics ( Site 0037)

    Madison, Wisconsin

  • Centro de Urología (CDU) ( Site 1552)

    Buenos Aires, Argentina

  • Hospital Británico de Buenos Aires-Oncology ( Site 1551)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Hospital Italiano de Buenos Aires ( Site 1554)

    ABB, Buenos Aires F.D., Argentina

  • Asociación de Beneficencia Hospital Sirio Libanés ( Site 1553)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1558)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Fundacion Estudios Clinicos-Oncology ( Site 1557)

    Rosario, Santa Fe Province, Argentina

  • Macquarie University-MQ Health Clinical Trials Unit ( Site 1259)

    Macquarie University, New South Wales, Australia

  • Mater Hospital Brisbane ( Site 1257)

    South Brisbane, Queensland, Australia

  • Lyell McEwin Hospital ( Site 1252)

    Elizabeth Vale, South Australia, Australia

  • Frankston Hospital-Oncology and Haematology ( Site 1258)

    Frankston, Victoria, Australia

  • Complex Oncology Center Plovdiv ( Site 1151)

    Plovdiv, Bulgaria

  • MHAT Central Onco Hospital OOD ( Site 1158)

    Plovdiv, Bulgaria

  • MHAT Serdika ( Site 1152)

    Sofia, Bulgaria

  • MHAT "Uni Hospital" OOD ( Site 1154)

    Panagyurishte, Pazardzhik, Bulgaria

  • BC Cancer - Vancouver Center ( Site 0110)

    Vancouver, British Columbia, Canada

  • CancerCare Manitoba ( Site 0108)

    Winnipeg, Manitoba, Canada

  • Moncton Hospital ( Site 0107)

    Moncton, New Brunswick, Canada

  • Ottawa Hospital Research Institute ( Site 0109)

    Ottawa, Ontario, Canada

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.